Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bioequivalence Study of the Test Preparation Olanzapine Samidofen Tablets Versus the Reference Preparation Olanzapine Samidofen Tablets (LYBALVI®) in Healthy Subjects Under Fasting Conditions.

NCT07922070 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07922070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Bioequivalence Study of the Test Preparation Olanzapine Samidofen Tablets Versus the Reference Preparation Olanzapine Samidofen Tablets (LYBALVI®) in Healthy Subjects Under Fasting Conditions.
Lead sponsor
The Affiliated Hospital of Qingdao University
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2025
Completion date
November 15, 2025
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder

Arms

As registered; 2 arms.

  • Group A:Test (T)-Reference (R) ExperimentalTest Olanzapine Samidofen Tablets, reference (LYBALVI®) Olanzapine Samidofen Tablets
  • Group B: Reference (R)-Test (T) ExperimentalTest Olanzapine Samidofen Tablets, reference (LYBALVI®) Olanzapine Samidofen Tablets

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Peak plasma concentration (Cmax) From predose through 72 hours after each dose
  • the area under the concentration-time curve (AUC0-t ) From predose through 72 hours after each dose

Lead sponsor's other trials

The Affiliated Hospital of Qingdao University, most recent start first.